Lipocine Inc. Appoints Michael Grissinger to Board

What Happened

• Lipocine Inc. (LPCN) filed a Form 8‑K on August 3, 2026, reporting that its Board expanded to five members and appointed Michael Grissinger as a director, effective immediately.
• The Board determined Mr. Grissinger is an independent director under Nasdaq standards; he will serve until the next annual meeting or until earlier death, disqualification, resignation or removal.
• A press release about the appointment was issued and is attached to the filing.

Key Details

• Appointment date: August 3, 2026.
• Board size after appointment: five members.
• Compensation: initial stock option to purchase 2,000 shares of common stock; annual non‑employee director retainer of $55,000.
• No family relationships with company directors/executive officers and no direct or indirect material transactions requiring disclosure under Item 404(a).

Why It Matters

• Governance: Adding an independent director can strengthen board oversight and corporate governance, which investors watch for corporate oversight and decision-making quality.
• Financial impact: The disclosed compensation (a 2,000‑share option grant and $55,000 annual retainer) is modest; the filing does not report any material immediate financial effect.
• Transparency: The company filed the required 8‑K and included a press release, so investors have official disclosure of the change in board composition.